Comparative Pharmacology
Head-to-head clinical analysis: DITATE DS versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITATE DS versus STATROL.
DITATE-DS vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid